Friday, September 26, 2025 |
| 7:00am |
Check-in and Breakfast in Exhibit Hall |
| 8:00am | Horizon CME App Overview and CE Housekeeping |
| 8:10am | Welcome, Introductions, & CE Housekeeping |
| 8:15am | (01) The Daniel D. Von Hoff Keynote Lecture: TBA
» TBA |
| 9:15am | Break | Refreshments in Exhibit Hall |
| | Block One: Small Molecules and Targeted Therapy |
| 9:40am | (02) Emerging Role of KAT6 Inhibitors in Cancer
» Patricia LoRusso, DO – Professor of Medicine (Medical Oncology); Chief, Experimental Therapeutics; Associate Cancer Center Director, Experimental Therapeutics Yale Cancer Center |
| 10:00am | (03) New Drugs in Lymphoma or subsets of Sarcomas
Products from the clinical side / substitute products for MTAP + Bispecifics
» TBA |
| 10:20am | (04) New USP1 and Selected PARP Inhibitors
» TBA |
| 10:40am | (05) Q+A Panel and Discussion: Block One
» Faculty from Sessions 02 – 04 |
| 11:00am |
Gather for Lunch |
| 11:10am | Lunch |
| 11:55am | Dessert – Refreshments in Exhibit Hall |
| | Block Two: Emerging Immunotherapeutic Platforms |
| 12:10pm | (06) Emerging Role of Peptides and NeoAntigen Vaccines
» Keith Knutson, PhD – Immunologist Mayo Clinic |
| 12:30pm | (07) Cell Therapy for Solid Tumors
» Elena Garralda, MD – Medical Oncologist, Director, Early Drug Development Unit, Co-Director of VHIO’s Clinical Research Program Director of the Phase I Unit, Vall d’Hebron Institute of Oncology, NEXT Oncology |
| 12:50pm | (08) Q+A Panel and Discussion: Block Two
» Faculty for Sessions 06 – 07 |
| 1:10pm | Message from the Cancer Charities |
| 1:25pm | Break – Trivia for Charity in the Exhibit Hall |
| | Block Three: Recent Precision Medicine Advances in Hematology/Oncology |
| 1:45pm | (09) Lung Cancers
» Mihaela Aldea, MD, PhD – Assistant Professor, International Center of Thoracic Cancers, Paris Saclay University Medical Oncologist Gustave Roussy |
| 2:05pm | (10) Breast Cancers
» TBA |
| 2:25pm | (11) GI Cancers
» Mitesh Borad, MD – Professor of Medicine Mayo Clinic College of Medicine and Science |
| 2:45pm | (12) Acute Leukemia or MDS MPNS
» Eytan Stein, MD – Hematologist-Oncologist Director, Drug Development in Leukemia Memorial Sloan Kettering Cancer Center |
| 3:05pm | (13) Q+A Panel and Discussion: Block Three
» Faculty from Sessions 09 – 12 |
| | Block Four: Clinical Advances in RAS Targeting |
| 3:25pm | (14) RAS ON Inhibitors
» Shubham Pant, MD, MBBS – Professor, Department of Gastrointestinal (GI) Medical Oncology The University of Texas MD Anderson Cancer Center |
| 3:45pm | (15) RAS Protacs and Molecular Glues
» TBA |
| 4:05pm | (16) RAS Enzymatic Inhibitors
» TBA |
| 4:25pm | (17) Q+A Panel and Discussion: Block Four
» Faculty from Sessions 14 – 16 |
| 4:45pm | Networking Reception – Exhibit Hall |
Saturday, September 27, 2025 |
| 7:00am | Check-in |
| 7:55am | Horizon CME App Overview and CE Housekeeping |
| 8:00am | Welcome and Introductions |
| | Block Five: Biomarker Methodology in Cancer |
| 8:10am | (18) ctDNA Applications in Management of Advanced Disease Patients on Investigational Agents – heme perspective – Myeloma – MRD end point
» TBA |
| 8:30am | Gather for Breakfast |
| 8:35am | Breakfast Symposium sponsored by TBA
» TBA |
| 9:20am | Transition Break |
| 9:25am | (19) AI as a Predictive Model in Drug Targets
» Irbaz B. Riaz, MBBS, PhD – Oncologist Mayo Clinic |
| 9:45am | (20) How Biomarkers are used to Guide Treatment with Bispecifics
» TBA |
| 10:05am | (21) Digital Molecular Pathology
» Kurt Schalper, MD, PhD – Associate Professor of Pathology, Director, Translational Immuno-oncology Laboratory Yale School of Medicine |
| 10:25am | (22) Q+A Panel and Discussion: Block Five
» Faculty from Sessions 18 – 21 |
| 10:45am | Break – Refreshments in the Exhibit Hall |
| 11:05am | Poster Session |
| | Block Six: Clinical Trial Methodology |
| 11:50am | (23) Strategies for Patient Recruitment
» Kelly Bolton, MD, PhD – Assistant Professor Washington University |
| 12:10pm | (24) Novel Endpoints for Therapeutic Response in Early Phase Trials
» Jordi Rodon Ahnert, MD, PhD – Associate Professor, Investigational Cancer Therapeutics Division of Cancer Medicine The University of Texas MD Anderson Cancer Center |
| 12:30pm | (25) The Evolution of Agnostic Drug Approval: Where Are We Now?
» Vivek Subbiah, MD – Chief, Early-Phase Drug Development, Sarah Cannon Research Institute |
| 12:50pm | (26) Role of Patient Advocacy in Early Phase Trials
» TBA |
| 1:10pm | (27) Q+A Panel and Discussion: Block Six
» Faculty from Sessions 23 – 26 |
| 1:30pm | Gather for Lunch |
| 1:35pm |
Buffet Lunch & Non-CME/CE Presentation Sponsored by TBA
» TBA |
| 2:20pm | Dessert Break in Exhibit Hall |
| | Block Seven: RAS Targeting and Other Drugs Targeting the Cell Surface |
| 2:35pm | (28) Radiopharmaceuticals in Drug Development
» TBA |
| 2:55pm | (29) Innovations in HER2 Targeted Therapy
» Alison Schram, MD – Gynecologic Medical Oncologist, Early Drug Development Specialist Memorial Sloan Kettering Cancer Center |
| 3:15pm | (30) Pre-Clinical Considerations in ADC Development
» Daruka Mahadevan, MD, PhD – Professor of Medicine, Tenured, Chief, Division of Hematology/Medical Oncology, AT&T President’s Distinguished University Chair, Director, Institute for Drug Development, Associate Director Clinical Research Mays Cancer Center, University of Texas Health |
| 3:35pm | (32) Clinical Advances in ADC Development and Novel Payloads
» Toshio Shimizu, MD, PhD – Professor, Department of New Experimental Therapeutics Director, International Cancer New Drug Development Center Kansai Medical University Hospital Director of Clinical Research and CEO, NEXT Oncology JAPAN |
| 3:55pm | Break – Refreshments in the Exhibit Hall |
| 4:15pm | (32) Novel Combination Approaches for ADC Therapeutics + Novel ADC Targets in Solid Tumors
» TBA |
| 4:35pm | (33) Toxicity Management Considerations with Current ADC Landscape – combine with payloads
» Antonio Giordano, MD, PhD – Medical Oncologist, Clinical Investigator Dana-Farber Cancer Institute |
| 4:55pm | (34) Q+A Panel and Discussion: Block Seven
» Faculty from Sessions 28 – 33 |
| 5:15pm | Closing Comments |
